ZEPATIER
Total Payments
$5.8M
Transactions
16,958
Doctors
5,996
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $138,775 | 2 | 0 |
| 2023 | $174,546 | 2 | 0 |
| 2022 | $24,960 | 1 | 0 |
| 2021 | $184,475 | 5 | 0 |
| 2020 | $169,630 | 4 | 0 |
| 2019 | $419,838 | 28 | 15 |
| 2018 | $1.1M | 3,170 | 1,750 |
| 2017 | $3.5M | 13,746 | 5,492 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.6M | 52 | 45.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.3M | 802 | 40.4% |
| Food and Beverage | $391,608 | 14,799 | 6.8% |
| Travel and Lodging | $354,060 | 1,249 | 6.1% |
| Space rental or facility fees (teaching hospital only) | $50,400 | 28 | 0.9% |
| Consulting Fee | $11,675 | 9 | 0.2% |
| Education | $1,833 | 19 | 0.0% |
Payments by Type
General
$3.1M
16,906 transactions
Research
$2.6M
52 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| HCV and CKD Progression | Merck Sharp & Dohme Corporation | $512,604 | 0 |
| Mobilize Against Hep C Utilizing an innovative mobile medical unit to optimize HCV screening, staging, and linkage to care in Northern California | Merck Sharp & Dohme Corporation | $257,758 | 0 |
| A prospective cohort study to compare the effectiveness of a 12 week course of Zepatier in the treatment of genotype 1 and 4 hepatitis C infected patients with mild fibrosis seen in safety net medical clinics including people who inject drugs compared to a retrospective cohort of patients treated in an hepatology clinic | Merck Sharp & Dohme Corporation | $209,654 | 0 |
| Effectiveness of Zepatier elbasvir EBR,grazoprevir GZR Ribavirin treatment for 16 weeks duration in chronic hepatitis C virus HCV genotype 1 GT1a-infected patients with selected baseline NS5A resistance associated polmorphisms,substitutions A retrospective analysis of the US Veterans Health Administration VHA National Data. | Merck Sharp & Dohme Corporation | $201,599 | 0 |
| Serology vs. Molecular Testing in Screening for Hepatitis C Virus Infection in Patients with Underlying Hematologic Malignancies and,or Hematopoietic Cell Transplant Recipients | Merck Sharp & Dohme Corporation | $171,973 | 0 |
| STUDY NAME#Developing a smartphone application to engage people who inject drugs PWID to promote HCV diagnosis, linkage to care and treatment | Merck Sharp & Dohme LLC | $163,121 | 0 |
| Modeling HCV,HIV Transmission and Treatment as Prevention in U.S. Networks of People Who Inject Drugs | Merck Sharp & Dohme Corporation | $143,735 | 0 |
| Mapping Hepatitis C Infections among Men Who Have Sex With Men in New York City an Epidemiologic Study | Merck Sharp & Dohme Corporation | $102,490 | 0 |
| Effectiveness of Zepatier Ribavirin treatment for 16 weeks duration in chronic hepaitis C virus genotype 1a-infected patients with selected baseline NS5A resistance associated polymorphism,substitutions A retrospective analysis of the US Veterans Health Administration National Data. | Merck Sharp & Dohme Corporation | $100,642 | 0 |
| Timing of Treatment for Chronic Hepatitis C Infection in Patients with End Stage Renal Disease Awaiting Transplantation | Merck Sharp & Dohme Corporation | $96,149 | 0 |
| Cost-effectiveness of Immediate Treatment of Acute HCV Infections among HIV-infected Men Who Have Sex with Men in the United States | Merck Sharp & Dohme Corporation | $91,401 | 0 |
| STUDY NAMEA prospective cohort study to compare the effectiveness of a 12 week course of Zepatier in the treatment of genotype 1 and 4 hepatitis C infected patients with mild fibrosis seen in safety net medical clinics including people who inject drugs compared to a retrospective cohort of patients treated in an hepatology clinic | Merck Sharp & Dohme Corporation | $89,852 | 0 |
| Real-world effectiveness and impact of elbasvir,grazoprevir on outcomes among HCV-infected patients | Merck Sharp & Dohme Corporation | $86,102 | 0 |
| STUDY NAME#HEP CARE Model for assessment and follow up of patients that screen positive for the HCV antibody during birth cohort screening at an urban health care system in New York City linkage and engagement in HCV Care | Merck Sharp & Dohme LLC | $79,300 | 0 |
| STUDY NAME#HEP CARE Model for assessment and follow up of patients that screen positive for the HCV antibody during birth cohort screening at an urban health care system in New York City linkage and engagement in HCV care | Merck Sharp & Dohme LLC | $59,475 | 0 |
| Ultra-deep Sequencing of NS5A Resistance Variants in HCV,HIV Coinfected Patients | Merck Sharp & Dohme Corporation | $54,651 | 0 |
| Education and Point of Care Diagnostics Increase Substance Users Initiation of HCV Care among Persons with Substance Use Disorders | Merck Sharp & Dohme Corporation | $51,929 | 0 |
| Demonstration of the feasibility of supported HCV treatment and eradication among persons with serious substance abuse disorders | Merck Sharp & Dohme Corporation | $34,020 | 0 |
| Cohort Study of Hepatitis C Virus Treatment with Zepatier Elbasvir,Grazoprevir in Genotype 1 or 4 HCV Treatment-Na or Peginterferon,Ribavirin-Experienced Patients with Substance Use in Urban, Multidisciplinary Specialty Clinics | Merck Sharp & Dohme Corporation | $31,485 | 0 |
| CHROME Study Cardiovascular disease in HIV and Hepatitis C Risk Outcomes after hepatitis C Eradication - A pilot, intervention, non-randomized, controlled prospective study to determine the role of Hepatitis C HCV infection on development of cardiovascular disease CVD in people living with HIV and HCV, and the impact of HCV eradication with DAAs on stabilization and regression of CVD. | Merck Sharp & Dohme Corporation | $29,120 | 0 |
Top Doctors Receiving Payments for ZEPATIER — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Hepatology | Miami, FL | $28,346 | 33 |
| , M.D | Infectious Disease | Bronx, NY | $27,971 | 22 |
| , M.D | Gastroenterology | Bronx, NY | $27,775 | 24 |
| , M.D | Gastroenterology | Indianapolis, IN | $27,567 | 26 |
| , MD | Infectious Disease | Madison, WI | $26,787 | 28 |
| , MD | Internal Medicine | Flushing, NY | $26,393 | 30 |
| , MD, MPH, FACP | Hepatology | Philadelphia, PA | $26,216 | 25 |
| , M.D | Hepatology | San Antonio, TX | $25,425 | 25 |
| , M.D | Gastroenterology | La Jolla, CA | $24,971 | 33 |
| , M.D | Gastroenterology | Colorado Springs, CO | $24,748 | 26 |
| , MD | Gastroenterology | Burr Ridge, IL | $23,766 | 38 |
| , M.D | Hepatology | Baltimore, MD | $23,712 | 25 |
| Imtiaz Alam | — | Austin, TX | $23,332 | 23 |
| , MD | Gastroenterology | Chicago, IL | $22,081 | 27 |
| , M.D | Internal Medicine | Louisville, KY | $22,066 | 14 |
| , DO | Gastroenterology | Allentown, PA | $21,962 | 38 |
| , MD | Hepatology | New York, NY | $21,114 | 20 |
| , D.O | Internal Medicine | Lansing, MI | $21,004 | 18 |
| , M.D | Internal Medicine | New Orleans, LA | $20,971 | 26 |
| , M.D | Gastroenterology | East Setauket, NY | $20,675 | 15 |
| , MD | Internal Medicine | New York, NY | $20,601 | 20 |
| , MD | Gastroenterology | Bronx, NY | $20,490 | 38 |
| , MD | Gastroenterology | Bronx, NY | $20,398 | 27 |
| , M.D | Hepatology | Coronado, CA | $20,263 | 18 |
| , MD | Transplant Hepatology | Phoenix, AZ | $19,908 | 22 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $5.5M
- Merck Sharp & Dohme LLC $338,281
Product Information
- Type Drug
- Total Payments $5.8M
- Total Doctors 5,996
- Transactions 16,958
About ZEPATIER
ZEPATIER is a drug associated with $5.8M in payments to 5,996 healthcare providers, recorded across 16,958 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2024. In 2024, $138,775 was paid across 2 transactions to 0 doctors.
The most common payment nature for ZEPATIER is "Unspecified" ($2.6M, 45.6% of total).
ZEPATIER is associated with 20 research studies, including "HCV and CKD Progression" ($512,604).